Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Frequently asked questions
What sector does SOL-GEL TECHN. IS-10 (4SG) operate in?
SOL-GEL TECHN. IS-10 belongs to the Healthcare sector and operates in the Biotechnology industry.
What is SOL-GEL TECHN. IS-10 (4SG) current stock price?
As of the latest data, SOL-GEL TECHN. IS-10 stock price is €60.50, with a previous close of €59.00. SOL-GEL TECHN. IS-10 gained €1.50 in the last trading session, representing a 2.54% increase.
What is SOL-GEL TECHN. IS-10 (4SG) current market capitalization?
SOL-GEL TECHN. IS-10 market cap is approximately 198.08 million.
What is SOL-GEL TECHN. IS-10 (4SG) Earnings Per Share (EPS)?
The trailing EPS is -€4.81.
What is SOL-GEL TECHN. IS-10 (4SG) EBITDA?
SOL-GEL TECHN. IS-10 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.64 million.
Does SOL-GEL TECHN. IS-10 (4SG) pay dividends?
No. SOL-GEL TECHN. IS-10 does not pay a dividend.
When is SOL-GEL TECHN. IS-10 (4SG) next earnings report?
SOL-GEL TECHN. IS-10 is expected to release its next earnings report on September 30, 2026.
What is SOL-GEL TECHN. IS-10 (4SG) beta (volatility) score?
SOL-GEL TECHN. IS-10 has a beta of 1.150, meaning its volatility is roughly in line with the market.
